NCT04704323View on ClinicalTrials.gov

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 10, 2021

Primary Completion Date

January 31, 2027

Study Completion Date

April 30, 2027

Conditions
Lymphocytic Leukemia, ChronicSLL
Interventions
DRUG

CAP-100

CAP-100 (humanized antibody against C-C-chemokine receptor 7 \[CCR\]7)

Trial Locations (4)

27705

RECRUITING

Duke University, Durham

28006

RECRUITING

Hospital Universitario de La Princesa, Madrid

39008

RECRUITING

Hospital Universitario Marqués de Valdecilla, Santander

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Catapult Therapeutics

INDUSTRY

NCT04704323 - CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter